Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AnaptysBio stock | 27.42

Own AnaptysBio stock in just a few minutes.


Fact checked

AnaptysBio, Inc is a biotechnology business based in the US. AnaptysBio shares (ANAB) are listed on the NASDAQ and all prices are listed in US Dollars. AnaptysBio employs 89 staff and has a trailing 12-month revenue of around USD$18 million.

How to buy shares in AnaptysBio

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for AnaptysBio. Find the stock by name or ticker symbol: ANAB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until AnaptysBio reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$27.42, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of AnaptysBio, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of AnaptysBio. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted AnaptysBio's share price?

Since the stock market crash in March caused by coronavirus, AnaptysBio's share price has had significant positive movement.

Its last market close was USD$27.42, which is 41.06% up on its pre-crash value of USD$16.16 and 127.36% up on the lowest point reached during the March crash when the shares fell as low as USD$12.06.

If you had bought USD$1,000 worth of AnaptysBio shares at the start of February 2020, those shares would have been worth USD$867.91 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,856.33.

AnaptysBio share price

Use our graph to track the performance of ANAB stocks over time.

AnaptysBio shares at a glance

Information last updated 2020-10-20.
Latest market close USD$27.42
52-week range USD$10 - USD$39.48
50-day moving average USD$16.638
200-day moving average USD$18.2575
Wall St. target price USD$20.5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.011

Buy AnaptysBio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AnaptysBio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AnaptysBio price performance over time

Historical closes compared with the close of $27.42 from 2020-11-16

1 week (2020-11-23) 9.24%
1 month (2020-10-30) -6.92%
3 months (2020-08-28) 61.96%
6 months (2020-05-29) 43.71%
1 year (2019-11-29) 103.26%
2 years (2018-11-30) -63.23%
3 years (2017-11-30) -67.38%
5 years (2015-11-26) N/A

AnaptysBio financials

Revenue TTM USD$18 million
Gross profit TTM USD$-91,338,000
Return on assets TTM -12.6%
Return on equity TTM -19.55%
Profit margin 0%
Book value $13.979
Market capitalisation USD$723.3 million

TTM: trailing 12 months

Shorting AnaptysBio shares

There are currently 4.3 million AnaptysBio shares held short by investors – that's known as AnaptysBio's "short interest". This figure is 6.8% down from 4.6 million last month.

There are a few different ways that this level of interest in shorting AnaptysBio shares can be evaluated.

AnaptysBio's "short interest ratio" (SIR)

AnaptysBio's "short interest ratio" (SIR) is the quantity of AnaptysBio shares currently shorted divided by the average quantity of AnaptysBio shares traded daily (recently around 262124.68007313). AnaptysBio's SIR currently stands at 16.41. In other words for every 100,000 AnaptysBio shares traded daily on the market, roughly 16410 shares are currently held short.

However AnaptysBio's short interest can also be evaluated against the total number of AnaptysBio shares, or, against the total number of tradable AnaptysBio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AnaptysBio's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 AnaptysBio shares in existence, roughly 160 shares are currently held short) or 0.2417% of the tradable shares (for every 100,000 tradable AnaptysBio shares, roughly 242 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AnaptysBio.

Find out more about how you can short AnaptysBio stock.

AnaptysBio share dividends

We're not expecting AnaptysBio to pay a dividend over the next 12 months.

AnaptysBio share price volatility

Over the last 12 months, AnaptysBio's shares have ranged in value from as little as $10 up to $39.48. A popular way to gauge a stock's volatility is its "beta".

ANAB.US volatility(beta: 0.79)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AnaptysBio's is 0.7937. This would suggest that AnaptysBio's shares are less volatile than average (for this exchange).

AnaptysBio overview

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; and collaboration with Celgene Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site